Igyxos S.A. has completed a Series A fundraising
Igyxos S.A. has completed a US$8.4 million fundraising as part of a Series A funding led by Bpifrance through its FABS Fund, with participation from the Go Capital Amorçage II and Loire Valley Invest Funds and by the Emergence Innovation II. This will allow the founder Marie Christine Maurel and Professor René Frydman, joined by Pierre-Henry Longeray (ex Merck Serono) as CEO, to pursue the proof of concept in human clinical practice.
Based in Nouzilly, France, biotechnology startup Igyxos is developing a new treatment for female and male infertility that works by shifting hormonal imbalances with a new method using monoclonal antibodies.
Oaklins’ team in France advised Igyxos on a "dual-track" project that allowed them to validate with the industry both scientific and therapeutic interest of its drug candidate based on the use of monoclonal antibodies to improve the treatment of female and male infertility.
Marie-Christine Maurel
CSO and Founder, Igyxos, S.A.
Talk to the deal team
Related deals
Top Systems teams up with Holland Capital to create the premier Dutch battery-based solutions provider
Holland Capital, a Netherlands-based private equity firm, has acquired a stake in Top Systems, a leading provider of complete battery-based power solutions, with a unique value-added services proposition.
Learn moreInfotreasury has been sold to Matera
Matera, a leading banking software company with world-class instant payments and core banking solutions, has acquired Infotreasury.
Learn moreThrive Freeze Dry has successfully sealed the acquisition deal with Paradiesfrucht GmbH
Paradiesfrucht GmbH, a gobal freeze dryer of fruits, fruit preparations, drops, powders and granulates, has been acquired by Thrive Freeze Dry (Thrive), a portfolio company of Entrepreneurial Equity Partners (e2p) and Mubadala Capital. The transaction is expected to close in 2024, subject to customary closing conditions, including antitrust approval.
Learn more